



MEN

FIRST CANCER SITE
SKIN MELANOMA

SKIN MELANOMA
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

MELANOMA CUTANEO
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	16345		16851		16851		16345		13847		6312		2312		16345	16851
Person-years ▶	79529		82299		2770		12567		38061		20175		8726		79529	82299
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND SKIN MELANOMA	1117	1.01	1183	1.03	66	1.77	210	1.24	517	1.01	272	0.95	118	0.84	0.12	0.46
HEAD AND NECK	31	0.62	32	0.62	1	0.58	8	1.02	18	0.77	4	0.32	1	0.17	-0.24	-0.24
ORAL CAVITY	5	0.41	5	0.40	0	0.00	1	0.53	3	0.53	1	0.32	0	0.00	-0.09	-0.09
PHARYNX	9	0.79	9	0.76	0	0.00	4	2.27	4	0.75	1	0.34	0	0.00	-0.03	-0.03
LARYNX	17	0.65	18	0.66	1	1.07	3	0.71	11	0.88	2	0.30	1	0.33	-0.12	-0.11
OESOPHAGUS	8	0.66	8	0.64	0	0.00	2	1.05	2	0.35	2	0.65	2	1.35	-0.05	-0.06
STOMACH	60	0.96	62	0.95	2	0.89	12	1.19	29	0.99	9	0.57	10	1.33	-0.03	-0.04
COLON RECTUM	134	0.87	137	0.86	3	0.59	18	0.77	63	0.90	38	0.95	15	0.75	-0.24	-0.26
COLON	91	0.87	92	0.85	1	0.29	10	0.63	37	0.77	31	1.13	13	0.94	-0.18	-0.20
RECTUM	43	0.89	45	0.90	2	1.23	8	1.08	26	1.17	7	0.56	2	0.33	-0.07	-0.06
LIVER	21	0.47	23	0.50	2	1.32	3	0.44	7	0.34	8	0.70	3	0.53	-0.30	-0.28
GALLBLADDER	13	1.16	14	1.21	1	2.59	3	1.71	6	1.16	3	1.05	1	0.71	0.02	0.03
PANCREAS	32	1.06	34	1.09	2	1.97	3	0.65	15	1.08	8	1.02	6	1.54	0.02	0.03
LUNG	140	0.74	159	0.81	19	2.89	35	1.18	52	0.59	36	0.75	17	0.73	-0.62	-0.45
SKIN MELANOMA	1	0.05	1	0.05	0	0.00	0	0.00	0	0.00	0	0.00	1	0.39	-0.23	-0.23
MESOTHELIOMA	12	1.93	13	2.03	1	4.98	2	2.18	7	2.48	2	1.22	1	1.21	0.07	0.08
KAPOSI SARCOMA	1	0.39	1	0.38	0	0.00	0	0.00	1	0.83	0	0.00	0	0.00	-0.02	-0.02
SOFT TISSUE	6	1.38	7	1.56	1	6.91	0	0.00	5	2.49	1	0.89	0	0.00	0.02	0.03
BONE	6	5.27	6	5.09	0	0.00	3	16.48	2	3.70	0	0.00	1	7.77	0.06	0.06
BREAST	5	2.03	5	1.96	0	0.00	0	0.00	2	1.76	3	4.67	0	0.00	0.03	0.03
PROSTATE	259	1.17	267	1.17	8	1.13	42	1.30	116	1.16	72	1.23	29	0.97	0.48	0.48
TESTIS	1	0.31	1	0.30	0	0.00	0	0.00	1	0.61	0	0.00	0	0.00	-0.03	-0.03
KIDNEY AND RENAL PELVIS	72	1.92	85	2.19	13	10.57	20	3.56	36	2.08	13	1.32	3	0.62	0.43	0.56
BLADDER AND URINARY TRACT	120	0.99	121	0.96	1	0.24	28	1.49	60	1.07	26	0.84	6	0.39	-0.02	-0.05
URINARY BLADDER	116	1.00	117	0.97	1	0.25	27	1.50	58	1.08	25	0.84	6	0.41	0.00	-0.04
URINARY TRACT	4	0.78	4	0.75	0	0.00	1	1.25	2	0.84	1	0.76	0	0.00	-0.01	-0.02
BRAIN AND CENTRAL NERVOUS SYSTEM	16	1.13	17	1.16	1	2.09	2	0.92	6	0.91	6	1.64	2	1.15	0.02	0.03
THYROID	28	3.97	29	3.99	1	4.49	7	6.86	14	4.33	5	2.65	2	2.20	0.26	0.26
HODGKIN LYMPHOMA	4	1.29	5	1.55	1	9.13	2	4.02	0	0.00	1	1.28	1	2.96	0.01	0.02
NON-HODGKIN LYMPHOMA	42	1.23	45	1.28	3	2.64	4	0.77	21	1.33	9	1.02	8	1.86	0.10	0.12
MYELOMA	19	1.31	20	1.34	1	2.04	4	1.79	8	1.20	5	1.34	2	1.08	0.06	0.06
LEUKAEMIAS	25	1.00	25	0.96	0	0.00	6	1.52	14	1.20	4	0.63	1	0.32	0.00	-0.01
LYMPHOID LEUKAEMIAS	14	1.16	14	1.12	0	0.00	4	2.10	8	1.42	2	0.65	0	0.00	0.02	0.02
MYELOID LEUKAEMIAS	10	0.87	10	0.85	0	0.00	2	1.13	5	0.95	2	0.68	1	0.70	-0.02	-0.02
OTHER LEUKAEMIAS	1	0.64	1	0.62	0	0.00	0	0.00	1	1.35	0	0.00	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	62	1.10	67	1.15	5	2.58	6	0.68	32	1.22	17	1.17	7	0.98	0.07	0.10

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
SKIN MELANOMA
SKIN MELANOMA
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

MELANOMA CUTANEO
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
	No. of subjects alive at interval beginning ▶	18162	18601		18601		18162		15921		8507		3575		18162	18601
Person-years ▶	105155	108222		3066		14166		47376		28905		14708		105155	108222	
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND SKIN MELANOMA	1008	1.17	1054	1.20	46	2.00	146	1.37	423	1.16	275	1.13	164	1.14	1.42	1.60
HEAD AND NECK	15	1.31	16	1.36	1	3.30	3	2.13	5	1.03	6	1.84	1	0.51	0.03	0.04
ORAL CAVITY	8	1.33	9	1.46	1	6.38	2	2.75	4	1.59	1	0.58	1	0.96	0.02	0.03
PHARYNX	3	1.09	3	1.06	0	0.00	0	0.00	0	0.00	3	3.83	0	0.00	0.00	0.00
LARYNX	4	1.46	4	1.42	0	0.00	1	2.95	1	0.86	2	2.58	0	0.00	0.01	0.01
OESOPHAGUS	3	0.77	3	0.75	0	0.00	2	4.12	0	0.00	1	0.91	0	0.00	-0.01	-0.01
STOMACH	45	1.00	46	1.00	1	0.78	11	1.87	20	1.04	9	0.73	5	0.69	0.00	0.00
COLON RECTUM	136	1.09	138	1.08	2	0.60	14	0.91	49	0.93	39	1.10	34	1.57	0.11	0.09
COLON	102	1.14	103	1.12	1	0.42	9	0.82	37	0.99	32	1.26	24	1.54	0.12	0.10
RECTUM	34	0.96	35	0.96	1	1.04	5	1.13	12	0.80	7	0.70	10	1.67	-0.01	-0.01
LIVER	17	0.85	17	0.82	0	0.00	1	0.40	9	1.07	4	0.71	3	0.86	-0.03	-0.03
GALLBLADDER	8	0.50	8	0.49	0	0.00	1	0.49	6	0.88	0	0.00	1	0.37	-0.08	-0.08
PANCREAS	31	0.99	31	0.97	0	0.00	1	0.26	15	1.16	10	1.12	5	0.89	0.00	-0.01
LUNG	69	1.30	82	1.51	13	9.62	12	1.91	28	1.28	18	1.18	11	1.15	0.15	0.26
SKIN MELANOMA	1	0.05	1	0.05	0	0.00	0	0.00	1	0.12	0	0.00	0	0.00	-0.18	-0.18
MESOTHELIOMA	4	1.76	5	2.15	1	17.66	0	0.00	1	1.07	1	1.53	2	4.75	0.02	0.02
KAPOSI SARCOMA	2	1.95	2	1.90	0	0.00	1	7.63	0	0.00	0	0.00	1	5.72	0.01	0.01
SOFT TISSUE	10	2.60	10	2.53	0	0.00	1	2.08	4	2.42	2	1.84	3	4.74	0.06	0.06
BONE	1	0.95	1	0.93	0	0.00	0	0.00	0	0.00	1	3.46	0	0.00	0.00	0.00
BREAST	329	1.32	342	1.34	13	1.98	32	1.05	141	1.33	101	1.43	55	1.35	0.77	0.80
CERVIX UTERI	9	0.66	9	0.64	0	0.00	2	1.08	3	0.49	2	0.53	2	1.05	-0.04	-0.05
CORPUS UTERI	44	1.06	45	1.06	1	0.91	5	0.98	20	1.14	14	1.19	5	0.72	0.02	0.02
OVARY	28	0.98	29	0.99	1	1.29	11	3.06	9	0.73	7	0.87	1	0.22	0.00	0.00
KIDNEY AND RENAL PELVIS	38	1.85	38	1.80	0	0.00	17	6.89	13	1.52	8	1.36	0	0.00	0.17	0.16
BLADDER AND URINARY TRACT	42	1.39	43	1.39	1	1.25	6	1.62	21	1.66	11	1.28	4	0.76	0.11	0.11
URINARY BLADDER	39	1.39	40	1.39	1	1.34	6	1.74	20	1.70	9	1.13	4	0.81	0.10	0.10
URINARY TRACT	3	1.43	3	1.39	0	0.00	0	0.00	1	1.14	2	3.37	0	0.00	0.01	0.01
BRAIN AND CENTRAL NERVOUS SYSTEM	11	0.87	11	0.85	0	0.00	0	0.00	3	0.56	4	1.12	4	1.89	-0.02	-0.02
THYROID	34	1.50	34	1.46	0	0.00	5	1.79	19	1.94	9	1.38	1	0.28	0.11	0.10
HODGKIN LYMPHOMA	3	1.01	4	1.30	1	10.84	1	2.36	1	0.72	1	1.26	0	0.00	0.00	0.01
NON-HODGKIN LYMPHOMA	37	1.15	42	1.28	5	5.87	3	0.76	16	1.18	11	1.21	7	1.29	0.05	0.08
MYELOMA	15	1.09	17	1.20	2	5.40	5	2.92	4	0.69	2	0.51	4	1.68	0.01	0.03
LEUKAEMIAS	23	1.16	24	1.18	1	1.82	3	1.19	12	1.41	5	0.90	3	0.92	0.03	0.03
LYMPHOID LEUKAEMIAS	11	1.29	11	1.25	0	0.00	1	0.91	5	1.36	2	0.84	3	2.17	0.02	0.02
MYELOID LEUKAEMIAS	12	1.23	13	1.29	1	3.78	2	1.63	7	1.68	3	1.08	0	0.00	0.02	0.03
OTHER LEUKAEMIAS	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	0	0.00	-0.01	-0.01
OTHER AND ILL DEFINED SITES	54	0.91	57	0.94	3	1.90	9	1.10	24	0.98	9	0.55	12	1.21	-0.05	-0.03

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio